Literature DB >> 21778139

CDK7 and CCNH are components of CDK-activating kinase and are required for meiotic progression of pig oocytes.

Wataru Fujii1, Takanori Nishimura, Kiyoshi Kano, Koji Sugiura, Kunihiko Naito.   

Abstract

CDK-activating kinase (CAK) phosphorylates threonine 161 (T161) of CDC2, a catalytic subunit of maturation/M-phase promoting factor (MPF), and is essential for MPF activation in mitosis. CAK has been thought to consist of a catalytic subunit, a regulatory subunit and an assembly factor: CDK7, CCNH (also known as cyclin H), and MNAT1 (also known as MAT1), respectively. Although it is known that the meiotic progression of oocytes is regulated by MPF activity, the role of CAK in meiosis is still unclear. In the present study, we attempted to confirm the involvement of CAK in the meiotic progression of porcine immature oocytes. The T161 phosphorylation of CDC2 was found around germinal vesicle breakdown (GVBD) and thereafter from 18 to 48 h of culture. The GVBD rate at 18 h was increased by the overexpression of CDC2 but not mutated CDC2 (T161 replaced by alanine). Transcripts of CDK7, CCNH, and MNAT1 were detectable throughout the culture period, and their protein distribution patterns during oocyte maturation were the same as those reported in mitotic somatic cells. Overexpression of CDK7 or CCNH accelerated the meiotic events, such as meiotic resumption, T161 phosphorylation of CDC2, CCNB (also known as Cyclin B) synthesis, and MPF activation. On the contrary, knockdown of CDK7 or CCNH caused the inhibition of these meiotic events. In contrast, overexpression and antisense RNA injection of MNAT1 had no influence on meiotic resumption, the status of T161 phosphorylation of CDC2, or MPF activity. These results suggest that CDK7 and CCNH activate CDC2 by T161 phosphorylation and make up CAK, which is required for normal meiotic progression during porcine oocyte maturation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21778139     DOI: 10.1095/biolreprod.111.091801

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  6 in total

1.  Interaction with CCNH/CDK7 facilitates CtBP2 promoting esophageal squamous cell carcinoma (ESCC) metastasis via upregulating epithelial-mesenchymal transition (EMT) progression.

Authors:  Jianguo Zhang; Junya Zhu; Lei Yang; Chengqi Guan; Runzhou Ni; Yuchan Wang; Lili Ji; Ye Tian
Journal:  Tumour Biol       Date:  2015-03-29

2.  Multiple-Tissue and Multilevel Analysis on Differentially Expressed Genes and Differentially Correlated Gene Pairs for HFpEF.

Authors:  Guofeng Zhou; Shaoyan Sun; Qiuyue Yuan; Run Zhang; Ping Jiang; Guangyu Li; Yong Wang; Xiao Li
Journal:  Front Genet       Date:  2021-07-08       Impact factor: 4.599

3.  Effects of exosome-like vesicles on cumulus expansion in pigs in vitro.

Authors:  Yuta Matsuno; Asuka Onuma; Yoshie A Fujioka; Kazuma Yasuhara; Wataru Fujii; Kunihiko Naito; Koji Sugiura
Journal:  J Reprod Dev       Date:  2017-02-05       Impact factor: 2.214

4.  Transcriptomic features of Pecten maximus oocyte quality and maturation.

Authors:  Marianna Pauletto; Massimo Milan; Arnaud Huvet; Charlotte Corporeau; Marc Suquet; Josep V Planas; Rebeca Moreira; Antonio Figueras; Beatriz Novoa; Tomaso Patarnello; Luca Bargelloni
Journal:  PLoS One       Date:  2017-03-02       Impact factor: 3.240

5.  Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation.

Authors:  Xiaoliang Zhao; In-Kyu Kim; Bhaskar Kallakury; Joeffrey J Chahine; Eiji Iwama; Mariaelena Pierobon; Emanuel Petricoin; Justine N McCutcheon; Yu-Wen Zhang; Shigeki Umemura; Vincent Chen; Changli Wang; Giuseppe Giaccone
Journal:  Mol Oncol       Date:  2021-01-26       Impact factor: 6.603

6.  Carrying-over effects of GVBD blocking on post-blocking meiotic progression of oocytes: species difference and the signaling pathway leading to MPF activation.

Authors:  Guang-Zhong Jiao; Hua-Yu Lian; Yan Gao; Ming-Ju Sun; Shuai Gong; Liang-Liang Zheng; Chuan-Xin Zhang; Jing-He Tan
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.